Activity-guided development of potent and selective toll-like receptor 9 antagonists

Area of Science:

• Immunology
• Medicinal Chemistry

Background:

• Toll-like receptor 9 (TLR9) is a key innate immune receptor implicated in autoimmune diseases, metabolic disorders, and sepsis.
• Currently, specific TLR9 antagonists for clinical use are unavailable, highlighting a significant therapeutic gap.

Purpose of the Study:

• To identify potent and selective inhibitors of human TLR9 (hTLR9) by exploring structure-activity relationships within a quinazoline scaffold.
• To evaluate the therapeutic potential of novel hTLR9 antagonists in preclinical models.

Main Methods:

• Systematic modification of quinazoline scaffold substitution patterns to optimize hTLR9 inhibitory activity.
• Assays using human peripheral blood mononuclear cells (hPBMC) and reporter cell lines to determine potency and selectivity against hTLR7.
• In vitro ADME profiling and pharmacokinetic studies.
• In vivo efficacy studies in a mouse model of TLR9-mediated response.

Main Results:

• Discovery of novel quinazoline derivatives achieving potent hTLR9 inhibition (< 50 nM).
• Demonstration of high selectivity (> 600-fold) against hTLR7, a related receptor with distinct functions.
• Favorable in vitro ADME and pharmacokinetic profiles were observed.
• Successful validation of hTLR9 antagonists in a relevant in vivo efficacy model in mice.

Conclusions:

• Specific physiochemical properties and substitution patterns in the quinazoline scaffold are crucial for potent and selective hTLR9 inhibition.
• The identified novel TLR9 antagonists possess promising therapeutic potential for diseases associated with aberrant TLR9 activation.
• These compounds represent viable drug candidates for further clinical development in relevant therapeutic areas.